Media.Player

Stem cells and stem cell-derived neurons as a model for studying Alzheimer's Disease

Summary

One major obstacle in the discovery of drugs for Alzheimer’s Disease (AD) is the lack of a renewable, physiologically relevant neuronal model that accurately recapitulates the pathophysiology of the disease. This technology establishes a homogenous and renewable primary neuronal model for studying AD in vitro. This model could be used for high throughput screening of small molecules for drug discovery and testing, as well as a cell-based research platform to study and identify new cellular pathways and targets for the treatment of AD.

Technology Benefits

Establishes a highly relevant and renewable AD neuronal cell modelContains AD related cellular machinery and can respond appropriately to pharmacological manipulationsGenerates physiologically relevant synapses between AD neuronsPatent Information:Patent Pending (WO/2012/122405Patent Pending (US 20140171380)Tech Ventures Reference: IR 2917

Technology Application

Cell-based, high-throughput assays to screen compounds for the treatment of Alzheimer’s Disease.Research tool for identifying therapeutic targets and pathways involved in Alzheimer’s Disease.

Detailed Technology Description

None

*Abstract

None

*Inquiry

Jerry KokoshkaColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

2917

*Principal Investigator

*Publications

McIntire LB, Landman N, Kang MS, Finan GM, Hwang JC, Moore AZ, Park LS, Lin CS, Kim TW. “Phenotypic assays for β-amyloid in mouse embryonic stem cell-derived neurons.” Chem Biol. 2013 Jul 25;20(7):956-67.Kim TW. “Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease.” Neurotherapeutics. 2015 Jan;12(1):132-42.

Country/Region

USA